Symposium

Print

  

Series of scientific lectures by Prof. Carsten Tschope
Paradigm shift in management of
heart failure

Novartis is a leading life-sciences company in the world, whose purpose is to reimagine medicine to improve and extend people’s lives. The Novartis vision is to be a trusted leader in changing the practice of medicine.

Continuing the legacy of scientifically enriched academic activities, Novartis engaged Prof. Carsten Tschope to deliver a series of lectures covering cardio-metabolic diseases in Faisalabad, Rawalpindi & Karachi.

Prof. Tschope is affiliated with Charite in Berlin, Germany. Charite is one of the largest university hospitals in Europe, boasting an excellent faculty. He is the Professor of Medicine & Cardiology and Vice Director of the department, having 250 publications to his name.


Prof. Carsten Tschope

The disease areas included heart failure, hypertension & diabetes and their management based on the latest and updated scientific evidence and guidelines.

The first program was held in Faisalabad on 29 March 2019 through live webcast, while the second & third programs took place in Rawalpindi and Karachi on 30 March & 31 March respectively, in which Prof. Tschope was present in person.

While discussing heart failure, Prof. Tschope meticulously explained the mode of action of sacubitril/valsartan, a first in class angiotensin receptor neprilysin inhibitor approved for treating chronic heart failure patients with reduced ejection fraction (HFrEF), belonging to New York Heart Association (NYHA) classification II-IV, who are symptomatic on current treatment.

The goals of heart failure treatment are to improve clinical status and quality of life, prevent hospital admissions and reduce mortality.

PARADIGM-HF, the landmark trial that is the largest mortality-morbidity trial in patients with HFrEF, showed the following results versus enalapril, correlating heart failure treatment goals mentioned above.

  • 20% reduction in cardiovascular mortality
  • 21% reduction in heart failure hospitalization
  • 16% reduction in all-cause mortality
  • Reduced symptoms and physical limitations of HF as indicated by Kansas City Cardiomyopathy Questionnaire (KCCQ) score
  • No important safety concerns

Based on PIONEER-HF, sacubitril/valsartan may be initiated in in-hospital patients after hemodynamic stabilization of patients with acute decompensated heart failure (ADHF).
This salt complex has Class I recommendation according to American & European guidelines.

Prof. Tschope also emphasised that cardiovascular risk is influenced by severity of hypertension, hypertension mediated organ damage (HMOD) and presence of co-morbidities such as diabetes and chronic kidney disease. He explained the importance of starting treatment in most patients with two (2) drugs, based on the latest guidelines, which placed single-pill combination therapy as the preferred strategy to improve treatment adherence.

All the programs were well-received by the participants which included doctors belonging to cardiology, internal medicine, endocrinology, nephrology and family medicine disciplines.

Novartis Pakistan would like to extend gratitude to all the participants.

References

  1. McMurray et al. N Engl J Med 2014.
  2. Velazquez et al. N Engl J Med 2018.
  3. Ponikowski et al. Eur Heart J 2016; 37:2129–200.
  4. Yancy et al. Circulation 2017; 136:e137–e161.
  5. Williams B, et al. Eur Heart J. 2018; 39:3021–3104.

PK1905684788

© Professional Medical Publications. All rights reserved.